Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Get Free Report) has earned an average recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $60.20.
A number of brokerages have recently weighed in on SUPN. Cantor Fitzgerald boosted their price objective on shares of Supernus Pharmaceuticals from $67.00 to $87.00 and gave the stock an “overweight” rating in a report on Wednesday, November 4th. Zacks Research lowered Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 3rd. Jefferies Financial Group began coverage on Supernus Pharmaceuticals in a report on Wednesday, November 4th. They set a “strong-buy” rating for the company. Weiss Ratings lowered Supernus Pharmaceuticals from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Friday, October 30th. Finally, Bank of America assumed coverage on shares of Supernus Pharmaceuticals in a research report on Monday. They set a “buy” rating and a $47.00 price objective on the stock.
Get Our Latest Stock Report on Supernus Pharmaceuticals
Hedge Funds Weigh In On Supernus Pharmaceuticals
Supernus Pharmaceuticals Trading Up 2.4%
Shares of NASDAQ SUPN opened at $29.45 on Friday. The stock has a market cap of $3.48 billion, a price-to-earnings ratio of 8.23, a P/E/G ratio of 0.58 and a beta of 0.84. Supernus Pharmaceuticals has a 1-year low of $25.92 and a 1-year high of $42.81. The stock’s 50-day moving average is $40.10 and its 200 day moving average is $46.50.
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) last issued its earnings results on Thursday, October 29th. The specialty pharmaceutical company reported $0.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.49 by ($0.14). Supernus Pharmaceuticals had a negative return on equity of 418.04% and a net margin of 32.75%. The firm had revenue of $208.60 million during the quarter, compared to analysts’ expectations of $217.56 million. During the same period in the prior year, the company earned ($0.80) EPS. The firm’s quarterly revenue was up 18.0% compared to the same quarter last year. On average, analysts forecast that Supernus Pharmaceuticals will post 3.80 EPS for the current fiscal year.
Supernus Pharmaceuticals Announces Dividend
The business also recently announced a special dividend, which was paid on Friday, November 6th. Stockholders of record on Friday, October 30th were given a $8.13 dividend.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders. Its work spans neurology and psychiatry, including therapies for epilepsy, attention-deficit/hyperactivity disorder (ADHD), and Parkinson’s disease. The company’s marketed products include Qelbree for ADHD; Oxtellar XR and Trokendi XR for epilepsy; and medicines for Parkinson’s disease, including Apokyn, Xadago, and Ongentys. Its portfolio also includes Gocovri, which is used to treat certain movement complications associated with Parkinson’s disease.
See Also
- Five stocks we like better than Supernus Pharmaceuticals
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
